Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Anti-Obesity Prescription Drugs market report explains the definition, types, applications, major countries, and major players of the Anti-Obesity Prescription Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Vivus
Arena Pharmaceuticals
Novo Nordisk A/s
Glaxosmithkline
Orexigen Therapeutics
Boehringer Ingelheim
F Hoffmann La Roche Ltd
Alizyme
By Type:
Orlistat
Phentermine and Topiramate
Bupropion and Naltrexone
Lorcaserin
Liraglutide
By End-User:
Pediatric
Adult
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Anti-Obesity Prescription Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Anti-Obesity Prescription Drugs Outlook to 2028- Original Forecasts
-
2.2 Anti-Obesity Prescription Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Anti-Obesity Prescription Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Anti-Obesity Prescription Drugs Market- Recent Developments
-
6.1 Anti-Obesity Prescription Drugs Market News and Developments
-
6.2 Anti-Obesity Prescription Drugs Market Deals Landscape
7 Anti-Obesity Prescription Drugs Raw Materials and Cost Structure Analysis
-
7.1 Anti-Obesity Prescription Drugs Key Raw Materials
-
7.2 Anti-Obesity Prescription Drugs Price Trend of Key Raw Materials
-
7.3 Anti-Obesity Prescription Drugs Key Suppliers of Raw Materials
-
7.4 Anti-Obesity Prescription Drugs Market Concentration Rate of Raw Materials
-
7.5 Anti-Obesity Prescription Drugs Cost Structure Analysis
-
7.5.1 Anti-Obesity Prescription Drugs Raw Materials Analysis
-
7.5.2 Anti-Obesity Prescription Drugs Labor Cost Analysis
-
7.5.3 Anti-Obesity Prescription Drugs Manufacturing Expenses Analysis
8 Global Anti-Obesity Prescription Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Anti-Obesity Prescription Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Anti-Obesity Prescription Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Anti-Obesity Prescription Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Anti-Obesity Prescription Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Orlistat Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Phentermine and Topiramate Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Bupropion and Naltrexone Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Lorcaserin Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Liraglutide Consumption and Growth Rate (2017-2022)
-
9.2 Global Anti-Obesity Prescription Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Pediatric Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Adult Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Anti-Obesity Prescription Drugs Market Analysis and Outlook till 2022
-
10.1 Global Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.2.2 Canada Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.2.3 Mexico Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.2 UK Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.3 Spain Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.4 Belgium Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.5 France Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.6 Italy Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.7 Denmark Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.8 Finland Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.9 Norway Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.10 Sweden Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.11 Poland Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.12 Russia Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.3.13 Turkey Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.2 Japan Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.3 India Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.4 South Korea Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.8 Thailand Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.9 Singapore Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.11 Philippines Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5.2 Colombia Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5.3 Chile Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5.4 Argentina Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5.6 Peru Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.6.3 Oman Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.6.4 Qatar Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.7.2 South Africa Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.7.3 Egypt Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.7.4 Algeria Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Anti-Obesity Prescription Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Anti-Obesity Prescription Drugs Consumption (2017-2022)
11 Global Anti-Obesity Prescription Drugs Competitive Analysis
-
11.1 Vivus
-
11.1.1 Vivus Company Details
-
11.1.2 Vivus Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Vivus Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.1.4 Vivus Anti-Obesity Prescription Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Arena Pharmaceuticals
-
11.2.1 Arena Pharmaceuticals Company Details
-
11.2.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.2.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Novo Nordisk A/s
-
11.3.1 Novo Nordisk A/s Company Details
-
11.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.3.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Glaxosmithkline
-
11.4.1 Glaxosmithkline Company Details
-
11.4.2 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Glaxosmithkline Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.4.4 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Orexigen Therapeutics
-
11.5.1 Orexigen Therapeutics Company Details
-
11.5.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.5.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Boehringer Ingelheim
-
11.6.1 Boehringer Ingelheim Company Details
-
11.6.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.6.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 F Hoffmann La Roche Ltd
-
11.7.1 F Hoffmann La Roche Ltd Company Details
-
11.7.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.7.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Alizyme
-
11.8.1 Alizyme Company Details
-
11.8.2 Alizyme Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Alizyme Anti-Obesity Prescription Drugs Main Business and Markets Served
-
11.8.4 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
12 Global Anti-Obesity Prescription Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Orlistat Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Phentermine and Topiramate Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Bupropion and Naltrexone Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Lorcaserin Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Pediatric Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Adult Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Anti-Obesity Prescription Drugs Market Analysis and Outlook to 2028
-
13.1 Global Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Anti-Obesity Prescription Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Anti-Obesity Prescription Drugs
-
Figure of Anti-Obesity Prescription Drugs Picture
-
Table Global Anti-Obesity Prescription Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Anti-Obesity Prescription Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Orlistat Consumption and Growth Rate (2017-2022)
-
Figure Global Phentermine and Topiramate Consumption and Growth Rate (2017-2022)
-
Figure Global Bupropion and Naltrexone Consumption and Growth Rate (2017-2022)
-
Figure Global Lorcaserin Consumption and Growth Rate (2017-2022)
-
Figure Global Liraglutide Consumption and Growth Rate (2017-2022)
-
Figure Global Pediatric Consumption and Growth Rate (2017-2022)
-
Figure Global Adult Consumption and Growth Rate (2017-2022)
-
Figure Global Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Table North America Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Figure United States Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Figure Germany Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Figure China Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Figure Brazil Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Anti-Obesity Prescription Drugs Consumption by Country (2017-2022)
-
Figure Australia Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Anti-Obesity Prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Vivus Company Details
-
Table Vivus Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Vivus Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table Vivus Anti-Obesity Prescription Drugs Product Portfolio
-
Table Arena Pharmaceuticals Company Details
-
Table Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Arena Pharmaceuticals Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
-
Table Novo Nordisk A/s Company Details
-
Table Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk A/s Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
-
Table Glaxosmithkline Company Details
-
Table Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Glaxosmithkline Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
-
Table Orexigen Therapeutics Company Details
-
Table Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Orexigen Therapeutics Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
-
Table F Hoffmann La Roche Ltd Company Details
-
Table F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
-
Table Alizyme Company Details
-
Table Alizyme Anti-Obesity Prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alizyme Anti-Obesity Prescription Drugs Main Business and Markets Served
-
Table Alizyme Anti-Obesity Prescription Drugs Product Portfolio
-
Figure Global Orlistat Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Phentermine and Topiramate Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Bupropion and Naltrexone Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lorcaserin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pediatric Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Adult Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Anti-Obesity Prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Anti-Obesity Prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
